What Notified Bodies Actually Check in Clinical Evaluations
Most manufacturers think the Notified Body review is about checking if you followed the template. It is not. The assessment is about whether your clinical evidence can defend the claims under regulatory pressure. That is a very different test.
In This Article
I have seen manufacturers spend months perfecting their clinical evaluation report format, only to receive deficiencies that question the entire logical foundation of their equivalence claim or the clinical relevance of their literature search.
The disconnect happens because most teams think about the CER as a document to complete. Notified Bodies think about it as a justification to defend. They are trained to find gaps in reasoning, not gaps in section headers.
Understanding what reviewers actually check changes how you build your clinical evidence file. It changes what you prioritize during the writing phase, and what you verify before submission.
The Assessment Framework They Use
Notified Body reviewers do not read your CER from page one to the end. They follow a specific assessment logic that tests the coherence of your clinical evidence chain.
The framework mirrors MDR Annex XIV requirements, but the execution reflects how claims fail under scrutiny. Reviewers look for logical breaks, unsupported leaps, and evidence that does not carry the weight you assign to it.
First, they verify whether your intended purpose is clear and measurable. If your claims are vague or layered with marketing language, the entire assessment stalls. They cannot evaluate clinical evidence if they cannot identify what clinical outcome you are claiming.
Then they check if your equivalence strategy holds before they look at your literature. Most deficiencies originate here.
Claiming equivalence based on similar intended purpose without demonstrating technical, biological, and clinical equivalence as defined in MDCG 2020-5. Reviewers will reject the equivalence pathway entirely if any pillar is missing or weakly justified.
Equivalence Claims Under Scrutiny
If you base your clinical evaluation on equivalence, the Notified Body reviewer will spend significant time on your equivalence justification. This is where most files break down.
They verify technical equivalence by comparing specifications, materials, design features, and performance data. If you state that devices are similar but provide no side-by-side comparison table with justifications for differences, the claim fails immediately.
Biological equivalence requires demonstration that materials in contact with the body produce comparable biological responses. A statement that both devices are biocompatible is not sufficient. Reviewers expect biocompatibility data for your specific device and a clear comparison to the equivalent device data.
Clinical equivalence is the most frequently underestimated pillar. You must show that the devices are used in the same clinical condition, in the same patient population, and produce the same clinical outcomes. If your device is used in a different anatomical location or if the patient population differs in disease severity, the equivalence pathway collapses.
Reviewers also check whether the equivalent device has sufficient clinical data itself. If you claim equivalence to a predicate that has weak clinical evidence, you inherit that weakness. The chain is only as strong as its weakest link.
Notified Bodies assess equivalence as a logical chain. If one link is missing or poorly justified, they will reject the entire equivalence pathway and require clinical investigation data. You cannot patch a failed equivalence claim with more literature.
Literature Review Assessment Logic
When reviewers assess your literature review, they do not count how many papers you included. They assess whether your search strategy could have identified all relevant clinical evidence.
They check your search terms, databases, date ranges, and inclusion criteria. If your search is too narrow or excludes databases where relevant studies are published, they will question the completeness of your evidence base.
Then they verify whether your appraisal was systematic and whether you applied consistent quality criteria. A literature table with no appraisal scores or inconsistent appraisal logic signals that the review was not rigorous.
Reviewers also look for evidence you excluded and why. If you excluded studies that report adverse events or conflicting outcomes without clear justification, that raises concerns about bias.
The most critical check is whether your literature actually addresses your specific device and intended purpose. Papers about similar technologies or related clinical conditions do not count as direct evidence unless you justify the transferability of results.
If your device is used in a specific patient subgroup or clinical setting not represented in the literature, reviewers will flag this as a gap. You cannot assume that general population data applies to your target population without justification.
Including literature on the general device class or technology without demonstrating relevance to the specific device under evaluation. Reviewers expect you to explain why each study is applicable to your device, not just related to the same clinical field.
State of the Art and Benefit-Risk Evaluation
The state of the art section is not a literature summary. It is a benchmark against which your device is assessed.
Reviewers check whether you identified current treatment options, alternative technologies, and clinical performance benchmarks. If your SOTA analysis is limited to devices similar to yours, you have missed the point. SOTA includes all options available to address the clinical condition.
They then evaluate whether your benefit-risk profile is favorable compared to existing options. If your device offers no clear clinical advantage or introduces new risks without compensating benefits, this will be questioned.
The benefit-risk assessment must be specific. General statements about safety and effectiveness are not sufficient. Reviewers expect quantified risks where possible, identified risk mitigation measures, and a clear explanation of why the benefits justify the residual risks.
If your PMCF plan does not address identified uncertainties or knowledge gaps, reviewers will require you to revise it. The PMCF plan is assessed as part of the overall clinical evidence strategy, not as a standalone document.
Notified Bodies assess whether your clinical evaluation conclusions are defensible if challenged by a competent authority. They simulate the scrutiny your file would face in an audit or incident investigation. If your logic does not hold under that pressure, you will receive deficiencies.
Clinical Evidence Sufficiency
The final and most consequential assessment is whether your clinical evidence is sufficient to support your claims and demonstrate compliance with General Safety and Performance Requirements.
Sufficiency is not a formula. It is a judgment based on device risk class, novelty, clinical claims, and the strength of available evidence. Reviewers assess this using the principles outlined in MDCG 2020-13.
For well-established device types with abundant clinical data and proven safety profiles, literature and equivalence may be sufficient. For novel devices, high-risk applications, or devices with limited clinical history, they will expect clinical investigation data.
Reviewers also check whether your evidence covers the full intended purpose and all patient populations. If you claim use in pediatric and adult patients but your evidence only covers adults, you have an evidence gap.
If your device has been modified since the clinical data was generated, reviewers will assess whether the modifications affect clinical performance or safety. If the impact is not evaluated, they will require additional data or investigation.
The sufficiency assessment also includes post-market data. If your device has been on the market and you have not systematically collected clinical performance and safety data, this will be flagged as a deficiency. PMCF is not optional under MDR.
What Happens When Deficiencies Are Issued
When a Notified Body issues a deficiency, they expect a structured response that addresses the root of the issue, not just the surface symptom.
If the deficiency questions your equivalence claim, adding more explanation without additional data will not resolve it. You need to provide the missing comparison data or acknowledge that equivalence cannot be demonstrated and propose an alternative pathway.
If the deficiency questions the completeness of your literature review, repeating the same search with minor adjustments will not be sufficient. You need to demonstrate that the new search strategy addresses the gap identified by the reviewer.
Deficiency responses are part of the assessment. Reviewers evaluate whether you understood the issue and whether your response demonstrates regulatory competence. Poor responses delay certification and damage credibility.
Most manufacturers underestimate how much time deficiency resolution adds to the timeline. A single fundamental deficiency can require months to resolve if it requires new data generation or clinical investigation.
Responding to deficiencies with explanations instead of evidence. Notified Bodies expect data and documented justifications, not narrative arguments about why your original submission was correct.
How to Prepare for the Assessment
The best way to prepare for Notified Body assessment is to conduct an internal review using the same logic reviewers will apply.
Before submission, verify that every claim in your intended purpose is supported by specific clinical evidence. Trace the evidence chain from claim to data source. If you cannot draw a direct line, the reviewer will not be able to either.
If you are using equivalence, verify that all three pillars are documented with objective data. Ask yourself if a reviewer with no prior knowledge of your device could reconstruct your equivalence logic from the documentation alone.
Review your literature search strategy and ask whether it could have missed relevant studies. If the answer is yes, revise the strategy before submission.
Check your benefit-risk evaluation for specificity. Replace general statements with quantified data and clear justifications. If you identify residual risks, ensure your PMCF plan addresses them.
Finally, ensure that your clinical evaluation is consistent with your risk management file, your technical documentation, and your IFU. Inconsistencies signal lack of control and will generate deficiencies across multiple documentation areas.
The Notified Body assessment is not an adversarial process. It is a verification that your clinical evidence strategy is sound and that your device can be placed on the market without unacceptable risk. If you build your clinical evaluation with that goal in mind, the assessment becomes a confirmation rather than a challenge.
But if you treat the CER as a document to complete rather than a justification to defend, the deficiencies will reveal that gap immediately.
Peace,
Hatem
Clinical Evaluation Expert for Medical Devices
Follow me for more insights and practical advice.
Frequently Asked Questions
What is a Clinical Evaluation Report (CER)?
A CER is a mandatory document under MDR 2017/745 that demonstrates the safety and performance of a medical device through systematic analysis of clinical data. It must be updated throughout the device lifecycle based on PMCF findings.
How often should the CER be updated?
The CER should be updated whenever significant new clinical data becomes available, after PMCF activities, when there are changes to the device or intended purpose, and at minimum during annual reviews as part of post-market surveillance.
What causes CER rejection by Notified Bodies?
Common reasons include inadequate equivalence demonstration, insufficient clinical data for claims, poorly structured SOTA analysis, missing gap analysis, and lack of clear benefit-risk determination. Structure and logical flow are as important as the data itself.
Which MDCG guidance documents are most relevant for clinical evaluation?
Key documents include MDCG 2020-5 (Equivalence), MDCG 2020-6 (Sufficient Clinical Evidence), MDCG 2020-13 (CEAR Template), MDCG 2020-7 (PMCF Plan), and MDCG 2020-8 (PMCF Evaluation Report).
Need Expert Help with Your Clinical Evaluation?
Get personalized guidance on MDR compliance, CER writing, and Notified Body preparation.
✌
Peace, Hatem
Your Clinical Evaluation Partner
Follow me for more insights and practical advice.
– MDR 2017/745 Annex XIV
– MDCG 2020-5 Clinical Evaluation – Equivalence
– MDCG 2020-13 Clinical Evaluation Assessment Report Template
